Compounded GLP-1s didn't die — the legal $139–$297 market, explained

The FDA is ending mass-produced compounded GLP-1s, but personalized prescriptions filled by traditional compounding pharmacies remain legal, and they now cost $139 to $297 a month all-in. Here is how the surviving market works, and when the brand is the smarter buy.

What the FDA actually shut down

On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from its 503B Bulks List. The proposal ran in the Federal Register on May 1. Comments closed July 30 after a one-month extension, and the rule is not final yet. The direction is unmistakable anyway.

Plain English: 503B "outsourcing facilities" are compounders that operate at near-factory scale. They can make large batches without a prescription for each patient, but only from raw ingredients on that bulks list, or while the brand drug is officially in shortage.

The semaglutide and tirzepatide shortages are over. The FDA's shortage database lists them as resolved, and no shortage means no shortage exception. Striking the three drugs from the bulks list would close the last door on mass-produced compounded GLP-1s, permanently.

The year's loudest warning shot involved Hims & Hers. It launched a $49-a-month compounded oral semaglutide in early February. Novo Nordisk sued on February 9. Hims settled on March 9, exited compounded GLP-1s entirely, and now operates as a storefront for the brand products.

Why compounded semaglutide is still legal right now

None of that touches the other kind of compounding. Under section 503A of federal drug law, a state-licensed pharmacy can compound a drug for one named patient, one prescription at a time. That pathway does not depend on the bulks list or on a shortage, and the FDA's proposal does not change it.

There are real conditions. A prescriber has to document a clinical reason this patient needs something the approved product does not offer, usually a modified dose or a different format. And the result cannot be "essentially a copy" of the FDA-approved drug. That is regulator-speak for: if it is basically Wegovy at Wegovy's doses, you cannot compound it just to sell it cheaper.

So the direct answer: yes, compounded semaglutide is legal to buy today, if it comes through a personalized 503A prescription that meets those conditions. The FDA is not winking at this. It is actively policing the boundary.

What "personalized" really means, and what's a sham

Legitimate personalization is a dose the manufacturer does not sell, a slower titration schedule than the standard products allow, or a format change with a documented reason. The chart note matters. It is the legal basis of the prescription.

Sham personalization is every customer receiving the identical "custom" formula, or a B12 add-in dropped into the vial for no reason except making the product look different from the brand. The FDA sent more than 30 warning letters this spring, many aimed at exactly that playbook. If a provider's personalization is automatic, identical, and unexplained, the FDA's view is that it is a copy with extra steps. A product like that can vanish mid-treatment when enforcement arrives.

The surviving market, priced

The legal 503A market as of our September 4 price checks, alongside the manufacturers' own direct-pay programs. "All-in" means the visit, the medication, and shipping are included. Rows run cheapest to priciest by standard full-dose monthly price.

Compounded products are not FDA-approved. Promotional first-month rates are noted but not used for ordering.

The honest math: when brand direct wins

Two years ago compounded semaglutide sold for under $150 while Wegovy listed at $1,349, and the decision made itself. Brand price cuts have collapsed that gap.

If a starter-dose pill fits your prescription, brand now wins on price. Wegovy's tablet starts at $149 through NovoCare, less than every month-to-month compounded plan on our list, and it is the FDA-approved product. Even the injectable pen's $199 promotional months undercut most of the compounded field. For many buyers, probably most new ones, brand direct is now the cheaper and simpler purchase.

So who still rationally buys compounded at $175 to $297? Four groups.

• Injectable buyers on a budget. The brand pen is $349 at standard pricing. Compounded injectables run $139 to $297.
• People who need doses the brands don't sell. Compounded pricing is typically flat across doses, while the brand pill climbs from $149 to $299. 503A pharmacies can fill in-between and very low doses, which is the whole legal point of the pathway. Noom's $179 microdose tier exists for that demand.
• Tirzepatide users. Lilly's direct price starts at $299 and tops out at $449, with no cheap entry dose. Compounded tirzepatide undercuts brand by far more than compounded semaglutide now does.
• People with an established provider. Some buyers stay for a clinician relationship or a format they prefer.

Which dose and format fit you is a conversation for your prescriber. The prices are our department, and the price case for compounding is narrower than it has ever been.

The safety trade-offs, stated plainly

A compounded drug is legal without being FDA-reviewed. No agency tests that specific formulation for safety, effectiveness, or consistency before it ships. Quality rests on the individual pharmacy, which answers to state inspectors, not to the FDA approval process.

Stanford Medicine clinicians published a blunt warning in July: untested additive combinations (their example, B12 chemically bonding with tirzepatide into a molecule found in no approved drug), dosing errors from patients drawing their own doses from vials, and no premarket check on what is in the syringe. The FDA has separately warned about compounders using semaglutide "salt forms," sodium and acetate variants that are different substances from the approved drug.

None of this means every compounded vial is dangerous. It means the burden of verification shifts to you.

Five checks before you buy from a compounded telehealth provider

1. Get the pharmacy's name before you pay. A legitimate provider tells you exactly which pharmacy fills the prescription, the way Cora names Hallandale and VialsRx. Refusal to name it ends the conversation.
2. Verify the license. Look the pharmacy up on its home state's board of pharmacy site and confirm it can ship to your state. NABP's safe.pharmacy search does this in one place.
3. Check third-party certification. LegitScript certification for the telehealth operation and PCAB accreditation for the pharmacy are the seals that are hard to fake. Verify on the certifier's own site, not the seller's badge.
4. Expect a real medical intake. Someone should take your history and document why you need a compounded dose or format. If nobody asks you anything, the personalization is the sham kind the FDA is targeting.
5. Do the exit math. Confirm the price is all-in, read the cancellation terms, and beware annual lock-ins. Trimi's $99 headline requires $1,188 upfront. Then compare the total against brand direct at your dose — our True-Cost Index keeps the current numbers.

What to watch next

The 503B exclusion is a proposal until the FDA finalizes it, and that could land any week. Expect more warning letters at the sham-personalization line, and expect the brands to keep using price as a weapon. NovoCare's $199 introductory months did more damage to the compounded value proposition than any Federal Register notice. We track every change in the changelog.

eDietAdvice may earn commissions from some links; rankings are ordered by price, never by compensation. This is pricing and legality journalism, not medical advice — dosing and treatment decisions belong with your prescriber.